Clinical Trial Update: Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of Immunotherapy

View source ↗

Summary

This entry describes a multi-centre retrospective, open-label study to validate ML-PrediCare in melanoma patients treated with first- or second-line immunothera…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ML-PrediCare

Snippet

Sponsor: Optimata Ltd. | Conditions: Melanoma | Status: UNKNOWN